| Autor: |
Zou Z; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Yin Y; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Lin J; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Hsu LC; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Brandon VL; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Yang F; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Jove R; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Jandial R; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and., Li G; Faculty of Health Sciences, University of Macau, China., Chen MY; Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center, Duarte, California; and. |
| Abstrakt: |
OBJECT Despite recent advances, metastatic melanoma remains a terminal disease, in which life-threatening brain metastasis occurs in approximately half of patients. Sorafenib is a multikinase inhibitor that induces apoptosis of melanoma cells in vitro. However, systemic administration has been ineffective because adequate tissue concentrations cannot be achieved. This study investigated if convection-enhanced delivery (CED) of sorafenib would enhance tumor control and survival via inhibition of the signal transducer and activator of transcription 3 (Stat3) pathway in a murine model of metastatic brain melanoma. METHODS Melanoma cells treated with sorafenib in vitro were examined for signaling and survival changes. The effect of sorafenib given by CED was assessed by bioluminescent imaging and animal survival. RESULTS The results showed that sorafenib induced cell death in the 4 established melanoma cell lines and in 1 primary cultured melanoma cell line. Sorafenib inhibited Stat3 phosphorylation in HTB65, WYC1, and B16 cells. Accordingly, sorafenib treatment also decreased expression of Mcl-1 mRNA in melanoma cell lines. Because sorafenib targets multiple pathways, the present study demonstrated the contribution of the Stat3 pathway by showing that mouse embryonic fibroblast (MEF) Stat3 +/+ cells were significantly more sensitive to sorafenib than MEF Stat3 -/- cells. In the murine model of melanoma brain metastasis used in this study, CED of sorafenib increased survival by 150% in the treatment group compared with animals receiving the vehicle control (p < 0.01). CED of sorafenib also significantly abrogated tumor growth. CONCLUSIONS The data from this study indicate that local delivery of sorafenib effectively controls brain melanoma. These findings validate further investigation of the use of CED to distribute molecularly targeted agents. |
